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RGS4 regulates partial agonism of the M2 muscarinic
receptor-activated K+ currents
I-Shan Chen1, Kazuharu Furutani1,2, Atsushi Inanobe1,2 and Yoshihisa Kurachi1,2
1Department of Pharmacology, Graduate School of Medicine and 2Center for Advanced Medical Engineering and Informatics, Osaka University, Japan
Key points
 Partial agonists produce a smaller response than full agonists even at 100% receptor occupancy.
 In G-protein-coupled receptor signalling, the submaximal efficacy of partial agonists is
determined by the conformational change of the agonist–receptor complex, which reduces
effector activation. However, it remains unclear whether the regulator of G-protein signalling
(RGS) proteins contribute to the partial agonism.
 By analysing the M2 muscarinic receptor (M2R)-activated G-protein-gated K+ inwardly
rectifying (KG) currents in a Xenopus oocyte expression system, pilocarpine acted as a partial
agonist in the presence of RGS4, as it did in rat atrial myocytes, while it acted like the full
agonist ACh in the absence of RGS4.
 Functional couplings within the agonist–M2R complex/G-protein/RGS4 system controlled the
relative efficacy of the agonists.
 Our findings help us to understand the molecular components andmechanism underlying the
partial agonism of M2R-mediated physiological responses.
Abstract Partial agonists are used clinically to avoid overstimulation of receptor-mediated
signalling, as they produce a submaximal response even at 100% receptor occupancy. The sub-
maximal efficacy of partial agonists is due to conformational change of the agonist–receptor
complex, which reduces effector activation. In addition to signalling activators, several regulators
help control intracellular signal transductions. However, it remains unclear whether these
signalling regulators contribute to partial agonism. Here we show that regulator of G-protein
signalling (RGS) 4 is a determinant for partial agonism of the M2 muscarinic receptor (M2R).
In rat atrial myocytes, pilocarpine evoked smaller G-protein-gated K+ inwardly rectifying (KG)
currents than those evoked by ACh. In a Xenopus oocyte expression system, pilocarpine acted as a
partial agonist in the presence ofRGS4 as it did in atrialmyocytes,while it acted like a full agonist in
the absence of RGS4. Functional couplings within the agonist–receptor complex/G-protein/RGS4
system controlled the efficacy of pilocarpine relative to ACh. The pilocarpine–M2R complex
suppressed G-protein-mediated activation of KG currents via RGS4. Our results demonstrate that
partial agonism of M2R is regulated by the RGS4-mediated inhibition of G-protein signalling.
This finding helps us to understand the molecular components and mechanism underlying the
partial agonism of M2R-mediated physiological responses.
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Introduction
Partial agonists are agonists thatproduce smaller responses
than full agonists even at 100% receptor occupancy.
Therefore, they can also act as a competitive antagonist
in the presence of a full agonist by competing for
receptor occupancy with higher affinity (Zahn et al.
2002; Zhu, 2005). Clinically, partial agonists are used
to avoid overstimulation of receptor-mediated signalling,
thereby decreasing side effects, and can be used in
addiction treatments, such as μ-opioid partial agonist
buprenorphine (Jasinski et al. 1978; Zhu, 2005).
In G-protein-coupled receptor (GPCRs) signalling,
effector activation is dynamically and oppositely tuned
by guanine nucleotide exchange factors (GEFs) and
GTPase-activating proteins (GAPs). GEFs promote the
formation of the active GTP-bound state of Gα subunits,
while GAPs accelerate GTP hydrolysis in the Gα subunits.
Previous studies suggested the partial agonism is due to
the lower efficiencies of GEFs when partial agonists bind
to specific receptors (Tota & Schimerlik, 1990; Seifert et al.
2001). Partial agonists induce a different conformational
change of the receptor from that induced by full agonists
(Seifert et al. 2001; Lape et al. 2008). The binding of
partial agonists stabilizes the receptor conformation and
decreases the affinity of the ligand–receptor complex for
Gα subunits, thereby reducing the ability to activate the
GEFs relative to full agonists (Tota & Schimerlik, 1990;
Seifert et al. 2001).
Although the role of GEFs in partial agonism has
been presented in many studies as described above, the
role of GAPs in partial agonism has not been discussed.
The regulator of G-protein signalling (RGS) proteins are
a family of well-known GAPs that negatively regulate
various G-protein-mediated signal pathways (Hepler,
1999; Ross & Wilkie, 2000). The physiological roles of
RGS proteins, especially RGS4, have been established in
studies of mammalian cardiomyocytes (Cifelli et al. 2008;
Hibino et al. 2010). RGS4 is involved in parasympathetic
signalling and heart rate control by modulating physio-
logical responses to the natural full agonist ACh via
M2R and G-protein-gated inwardly rectifying K+ (KG)
channels (Fujita et al. 2000; Inanobe et al. 2001; Ishii
et al. 2001; Cifelli et al. 2008). It is conceivable that
RGS-mediated negative regulation of G-protein signals
may also contribute to the partial agonism of muscarinic
ligands.
In the present study, we investigated the effect of
RGS4 on the M2R agonist-evoked KG currents in rat
atrial myocytes and Xenopus oocytes that expressed
M2Rs and cardiac-type KG channels (Kir3.1/Kir3.4)
with or without RGS4. Relative to the M2R full
agonist ACh, the M2R partial agonist pilocarpine
produces submaximal responses in several muscarinic
signalling pathways (Bymaster et al. 1999; Zahn
et al. 2002). We found that deficient RGS4 function
elevated the relative efficacy of pilocarpine to ACh
on KG currents. Disturbing the interaction within
the agonist–receptor complex/G-protein/RGS4 system
impaired the RGS4-mediated regulation and eliminated
the divergent efficacy between pilocarpine and ACh.
By co-expression of M2Rs and D2 dopamine receptors
(D2Rs), we found that pilocarpine conspicuously
suppressed the dopamine-evoked KG currents via M2Rs
andRGS4. This indicates that the binding of pilocarpine to
M2Rs promotes the RGS4-mediated negative regulation
of G-protein signalling. Our finding suggests that the
RGS-mediated inhibition of G-protein signals is one of
the components that underlies the partial agonism of
M2R-activated KG currents.
Methods
Ethical approval
All animal experiments were performed in accordance
with the guidelines for the use of laboratory animals
of Osaka University Graduate School of Medicine. The
experimental protocol, including the use of a combination
anaesthetic, was approved by the Institutional Animal
Care and Use Committee and the Animal Experiments
Committee of Osaka University. Adult male Wistar
rats (200–300 g) were adequately anaesthetized by
a combination anaesthetic (I.P., 0.3 mg kg−1 of
medetomidine, 4.0 mg kg−1 of midazolam, and
5.0 mg kg−1 of butorphanol; Kawai et al. 2011) after
injecting heparin (I.P., 1000 U kg−1).
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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Preparation of isolated atrial myocytes
Single atrial myocytes were enzymatically isolated from
hearts thatwere removed from rats as described previously
(Ishii et al. 2001). Briefly, a cannula was inserted into the
aorta, and the heart was perfused in a retrograde manner
through the coronary arteries. The heart was digested by
collagenase (Sigma, St. Louis, MO, USA) in nominally
Ca2+-free solution at 37°C for 10 min. Dissociated myo-
cytes were maintained in KB solution, which contained
(mM): 10 taurine, 10 oxalic acid, 70 glutamic acid, 25 KCl,
10 KH2PO4, 0.5 EGTA, 11 glucose, 10 Hepes; pH 7.3 with
KOH. Freshly isolated cells were used on the day.
Preparation of Xenopus oocytes expressing receptors,
channels and RGS proteins
Isolation and maintenance of the oocytes of frogs
(Xenopus laevis) and injection with complementary
RNA (cRNA) were performed as described previously
(Inanobe et al. 2001). The following constructs were
used in this study: porcine M2R, mouse Kir3.1,
rat Kir3.4, rat RGS4 and human D2R. Truncated
and site-directed mutants of RGS4 were produced
as described in Inanobe et al. (2001). Oocytes were
injected with cRNAs for M2R (80 ng oocyte−1), Kir3.1
(8 ng oocyte−1), Kir3.4 (8 ng oocyte−1), wild-type
RGS4 (160 ng oocyte−1) and various RGS4 mutants
(160ngoocyte−1). For co-expressionofD2RandM2R, the
injected concentrations (ngoocyte−1)were 80 forD2Rand
0.08–0.8 for M2R. After injection, oocytes were incubated
at 18°CinND96 solution,whichcontained (mM): 96NaCl,
2 KCl, 1.8 CaCl2, 1 MgCl2 and 5 Hepes; pH 7.6 with
NaOH, and supplemented with gentamicin (50 μg ml−1)
and sodium pyruvate (2.5 mM). Currents were recorded
3–5 days after the cRNA injection. In some experiments,
oocytes were incubated in 2–bromopalmitate (2–BP,
100 μM) for2 h before electrophysiological recordings.
Patch-clamp analysis
Membrane currents of rat atrialmyocyteswere recorded in
thewhole-cell configuration of the patch-clamp technique
by a patch-clamp amplifier (EPC10, HEKA Electro-
nics, Lambrecht, Germany) at room temperature. Data
were reproduced, low-pass-filtered at 1 kHz (−3 dB)
by an eight-pole Bessel filter, sampled at 5 kHz, and
analysed offline with PatchMaster (HEKA Electronics)
and FitMaster (HEKA Electronics). The bath solution
contained (mM): 115NaCl, 20 KCl, 1.8 CaCl2, 0.53MgCl2,
5.5 glucose and 5.5Hepes; pH 7.4 withNaOH. The pipette
solution contained (mM): 150 KCl, 5 EGTA, 1 MgCl2, 3
K2ATP, 0.1 Na2GTP and 5 Hepes; pH 7.3 with KOH. The
tip resistance of the glass electrodes was 2–5 M when
filled with the pipette solution.
Two-electrode voltage clamp
Membrane currents of oocytes were recorded using
the two-electrode voltage clamp by a GeneClamp 500
amplifier (Molecular Devices, Sunnyvale, CA, USA) at
room temperature. Data were reproduced and analysed
with pCLAMP 10 (Molecular Devices) and Clampfit 10.2
(Molecular Devices). The bath solution contained (mM):
90 KCl, 3 MgCl2, 0.15 niflumic acid and 5 Hepes; pH 7.4
with KOH. The tip resistance of the glass electrodes was
0.4–1.5 M when filled with the 3 M KCl pipette solution.
Data analysis
Agonist-induced currents were obtained by digitally sub-
tracting currents recorded under control conditions from
those recorded in the presence of agonists. Results are
shown as mean values obtained from n cells, and error
bars represent SEM. Statistical differences were evaluated
by Student’s t tests. Significance was indicated by P< 0.05.
Chemicals
Chemicals were purchased from Sigma-Aldrich.
CCG-50014 was purchased from Calbiochem. CCG-4986
was kindly provided by Dr Yoshiyuki Hari (Osaka
University). CCG-50014 and CCG-4986 were dissolved in
DMSO and diluted to a final solvent concentration 1%
in pipette solution and bath solution. 2–BP was dissolved
in ethanol and diluted to a final solvent concentration
0.1% in bath solution.
Results
Effects of RGS4 on ACh- and pilocarpine-evoked KG
currents
Werecorded theM2R full agonistACh-evokedKG currents
in rat atrial myocytes and found that 1 μM ACh evoked
a maximal KG current and showed a time-dependent
increase in current amplitude upon membrane hyper-
polarization (Fig. 1A, black trace), which is a characteristic
of ACh-evoked KG currents called ‘relaxation’ (Noma
& Trautwein, 1978; Yamada et al. 1998; Fujita et al.
2000). We next examined several M2R partial agonists
(including pilocarpine, bethanechol and oxotremorine)
and found that a clinically used cholinomimetic agent,
pilocarpine, gave the smallest KG currents relative to the
full agonist ACh-evoked KG currents (Fig. 1A and Fig. S1A
and B in the online Supporting information). Therefore,
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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we investigated the mechanism underlying the partial
agonism of pilocarpine.
Pilocarpine (100 μM) evoked a smaller saturated KG
current than did ACh in the same atrial myocyte and
showed a time-dependent decrease in current amplitude
from peak to steady state upon membrane hyper-
polarization (Fig. 1A, red trace). ApplyingM2R antagonist
atropine or KG channel blocker tertiapin-Q completely
inhibited the pilocarpine-evoked currents (Fig. 1B and
C).
To investigate whether RGS4 influences partial agonism
ofM2R, we tried to reconstitute the cardiac KG currents in
Xenopus oocytes that expressed cardiac-type KG channels,
the Kir3.1/Kir3.4 heteromultimer (Krapivinsky et al.
1995), and M2Rs with or without RGS4. The basal
receptor-independent KG currents were not influenced by
RGS4 expression. In the presence of RGS4, pilocarpine
evoked the submaximal response of steady-state current
that resembles the KG currents in atrial myocytes at
−100 mV (Fig. 1D). In the absence of RGS4, pilocarpine
evoked a larger steady-state current that almost equalled
the maximal response of ACh-evoked currents (Fig. 1E).
We observed a similar time-dependent decrease of
pilocarpine-evoked currents and the time-dependent
current increase of ACh-evoked currents (Fig. 1D) to
that of the atrial myocytes shown in Fig. 1A. However,
such a characteristic difference between pilocarpine- and
ACh-evoked currents was not shown in the oocytes
lacking RGS4 (Fig. 1E). This indicates that RGS4 is
essential for reconstituting the cardiac M2R-activated KG
currents. The elevation of steady-state current in the
absence of RGS4 suggests RGS4 inhibits M2R-activated
KG currents in response to pilocarpine. We also made
similar observations in other M2R partial agonist-evoked
KG currents (Supporting information Fig. S1C–F).
We tried to examine the involvement of RGS4 in partial
agonism in rat atrial myocytes by several small-molecule
inhibitors of RGS proteins, such as CCG-4986 and
CCG-50014 (Roman et al. 2007; Blazer et al. 2011).
However, these compounds showed no or little effect on
ACh- and pilocarpine-evoked KG currents in both atrial
myocytes and oocytes (data not shown), suggesting these
compounds could not influence the RGS4 function in
modulating KG currents in our experimental conditions.
Concentration–response relationship of
agonist-evoked KG currents
By applying ACh (0.001–10 μM) or pilocarpine
(0.1–100 μM), we observed faster activations and
deactivations of KG currents in the RGS4-expressing
oocytes than control oocytes (without RGS4; Fig. 2A
and C). This is consistent with previous findings that
RGS4 accelerates the time course of agonist-induced
activation and deactivation of KG currents (Doupnik
et al. 1997; Fujita et al. 2000). According to the
concentration–response curve, we found that RGS4
suppressed the efficacy of pilocarpine relative to ACh,
with values of 53% (with RGS4, Fig. 2B) compared to 94%
(without RGS4, Fig. 2D) at−60mV.The−logEC50 of ACh
was 7.95 ± 0.13 M with RGS4 and 8.23 ± 0.07 M without
RGS4; the −logEC50 of pilocarpine was 6.08 ± 0.08 M
with RGS4 and 6.36 ± 0.12 without RGS4. There was
A
0.5 s
1 nA
0 mV
–100 mV
–50 mV
100 µM pilocarpine 100 µM pilocarpine+
0.7 µM atropine
0.5 s
1 nA
100 µM pilocarpine+
0.1 µM tertiapin-Q
0.5 s
1 nA
B C
ED
1 µM ACh
1 µA
0.5 s
100 µM pilocarpine 100 µM pilocarpine
1 µA
0.5 s1 µM ACh
0 mV
–100 mV
+ RGS4 – RGS4
Figure 1. Effects of RSG4 on ACh- and
pilocarpine-evoked KG currents
A, 100 μM pilocarpine-evoked KG currents (red)
relative to 1 μM ACh-evoked KG currents (black)
in the same rat atrial myocyte. Whole-cell
currents were recorded with a voltage pulse
protocol as showed below the current traces
and basal currents were subtracted.
Arrowheads indicate the zero current level.
Pilocarpine (100 μM)-evoked currents were
blocked in the presence of 0.7 μM atropine (B)
or 0.1 μM tertiapin-Q (C) in atrial myocytes.
Agonist-evoked currents were recorded in the
same oocyte expressing M2Rs and the
Kir3.1/Kir3.4 heteromultimer with (D) and
without (E) RGS4 at −100 mV.
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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no significant difference in the −logEC50 of ACh and
pilocarpine regardless of the presence or absence of RGS4.
This indicates that the agonist affinity at M2R was not
influenced by RGS4 but the relative efficacy of pilocarpine
to ACh was elevated in the absence of RGS4. The
different efficacy between pilocarpine andAChwas almost
eliminated in the deficiency of RGS function, suggesting
RGS4-mediated inhibition is essential for partial agonism
of M2R-activated KG currents.
To test the idea in atrial myocytes, we examined
the effect of intracellular GTPγS, a non-hydrolysable
analogue of GTP. We found that the time-dependent
decrease of pilocarpine-evoked KG currents could be
eliminated by applying GTPγS (Supporting information
Fig. S2). The difference between the current amplitudes
of ACh- and pilocarpine-evoked KG currents was much
smaller in the presence of GTPγS when compared with
control conditions (Fig. 1). This suggests RGS4-mediated
inhibition of KG currents may be overcome by the
GTPγS-induced irreversible activation of KG channels.
Voltage dependence of response of pilocarpine
compared to ACh
Pilocarpine-evoked KG currents showed a distinct current
change upon the hyperpolarizing pulse compared to
the ACh-evoked KG currents in the presence of RGS4
(Fig. 1D). To examine the effect of membrane voltage
on partial agonism, we recorded the responses induced by
1 μM ACh and 100 μM pilocarpine in the same oocyte
with a step protocol (−20 mV to −100 mV, −20 mV
increments, 2 s) and evaluated the relative response of
pilocarpine to ACh at several membrane potentials. We
found that RSG4-mediated inhibition of KG currents in
response to pilocarpine was enhanced during membrane
hyperpolarization (Fig. 3A) and therefore the relative KG
currents evoked by pilocarpine to ACh were smaller at
the more negative potentials in the presence of RGS4
(Fig. 3C). Such voltage dependence in KG currents evoked
by pilocarpine relative to ACh was not observed in
the absence of RGS4, because the responses induced by
pilocarpine andAChwere about the same at each potential
(Fig. 3B and C). This suggests that the partial agonism of
M2R-activatedKG currents is voltagedependent andRGS4
plays a crucial role in the underlying mechanism.
Requirements of RGS4 domain for partial agonism
To clarify how RGS4 influences partial agonism, we
investigated the functional structure of RGS4 for partial
agonism. RGS proteins contain a conversed region, the
RGS domain, which is composed of 120–130 amino acid
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Figure 2. Concentration–response curve of pilocarpine and ACh
Currents were recorded in the presence of pilocarpine (0.1–100 μM) and ACh (0.001–10 μM) with a holding
potential of −60 mV in oocytes with (A) and without (C) expression of RGS4. The bars above each trace indicate
the periods and concentrations of application of ACh or pilocarpine. Dashed lines indicate the zero current level
and arrowheads indicate the basal current level. Concentration–response curves of pilocarpine and ACh in oocytes
with (B) or without (D) expression of RGS4. The average maximal response of ACh-evoked KG currents was set as
100%. The vertical axis indicates the relative percentages of response that were induced by each concentration of
agonists. Data show the means ± SEM, n = 6 at each concentration in both with and without RGS4 groups. All
symbols have attached error bars, but some of them are smaller than the symbol.
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residues that mediate interaction with pertussis toxin
(PTX)-sensitive Gα subunits and the effect of RGS4 on
the agonist concentration-dependent relaxation of KG
channels (Inanobe et al. 2001). On the other hand,
regions outside the RGS domain are divergent and may
regulate subcellular localization (Zheng et al. 1999). To
determine the structural requirements for partial agonism,
we examined several truncated RGS4 mutants.
Oocytes expressing wild-type RGS4 showed a partial
response to pilocarpine, but absence of RGS4 yielded a
response similar to the effect of the full agonist ACh at
−60mV (Fig. 4Aa, b andC). The truncated RGS4mutants
and a point mutation in RGS domain were constructed
as illustrated in Fig. 4B. The mutant RGS4/51-177 is
composed of only the RGS domain. Oocytes expressing
RGS4/51-177 showed a similar time-dependent decrease
of pilocarpine-evoked currents and the relative response of
pilocarpine to ACh (47%) as shown in oocytes expressing
wild-type RGS4 (Fig. 4Af and C). Mutants containing
the RGS domain and N-terminus (RGS4/1-177) or RGS
domain and C-terminus (RGS4/51-205) also produced a
similar relative response (51% and 48%; Fig. 4Ad, e and
C).However, themutants that did not contain the full RGS
domain (RGS4/1-50 and RGS4/85-177) showed elevated
relative responses (94% and 96%), which are closer to the
value observed in the absence of RGS4 (Fig. 4Ac, g and
C). Lack of the full RGS domain eliminated the efficacy
difference between pilocarpine and ACh, indicating that
the RGS domain is essential for RGS4-mediated inhibition
to control the partial agonism of M2R-activated KG
currents.
We next examined the effect of a point mutation in
the RGS domain (asparagine 128 to histidine, N128H;
Fig. 4B). The residue N128 is necessary for RGS4 function
and controls GAP activity. The RGS4/N128H mutation
impairs the effect of RGS4 by interfering in the inter-
action with Gα subunits (Natochin et al. 1998; Srinivasa
et al. 1998; Inanobe et al. 2001). In oocytes expressing
RGS4/N128H, pilocarpine evoked an inward current that
mildly decreased during hyperpolarization; the relative
response (91%)wasmuch higher than thewild-typeRGS4
group (Fig. 4Ah and C). This suggests that interaction
between the RGS domain and Gα subunits modulates the
partial agonism of M2R-activated KG currents.
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Figure 3. Voltage-dependence of relative response of pilocarpine to ACh
ACh (1 μM, a) and pilocarpine (100 μM, b)-evoked KG currents in oocytes with (A) and without (B) expression
of RGS4. Whole-cell currents were recorded with a step protocol as showed above the current traces and basal
currents were subtracted. Arrowheads indicate the zero current level. C, the pilocarpine (100 μM)-evoked KG
currents as a percentage of ACh (1 μM)-evoked KG currents at each membrane potential were calculated from
steady state. Filled circles indicate the oocytes expressing RGS4; open circles indicate absence of RGS. The graph
shows the means ± SEM, n = 6 for each condition.
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Functional couplings of RGS4 to plasma membrane
In addition to the RGS–Gα subunit interaction, the
functional coupling of the pilocarpine–M2R complex
and RGS proteins may also play an important role in
partial agonism because RGS proteins have been indicated
to interact with GPCRs, including M2R–RGS4 coupling
(Abramow-Newerly et al. 2006; Jae´n & Doupnik, 2006).
To investigate the influence of M2R–RGS4 coupling in
partial agonism, we disturbed the membrane localization
of RGS4 by application of 2–bromopalmitate (2-BP), an
inhibitor of palmitoyl-CoA transferase. 2–BP inhibits the
palmitoylation of RGS4 and results in the redistribution
of RGS4 from plasma membrane to cytosol (Wang et al.
2010; Bastin et al. 2012).
To confirm the effect of 2–BP, rat atrial myocytes and
Xenopus oocytes were pretreated with 2–BP (100 μM) for
longer than 2 h before electrophysiological recording. The
2–BP treatment severely weakened the plasma membrane
of myocytes and we failed to record the current pre-
cisely, while we found in oocytes that application of 2–BP
decelerated the activation anddeactivation ofACh-evoked
KG currents when compared with the vehicle (0.1%
ethanol) group in the RGS4-expressing oocytes (Fig. 5A
and B). This suggests that RGS4 function in this system
is indeed impaired by applying 2–BP. We next examined
the effect of 2–BP in partial agonism: pilocarpine evoked
smaller KG currents than ACh-evoked KG currents in
the vehicle group (Fig. 5C), while pilocarpine evoked
larger KG currents that almost equalled ACh-evoked KG
currents in the 2–BP-treated group (Fig. 5D). The efficacy
difference between pilocarpine and ACh was eliminated
by 2–BP-mediated redistribution of RGS4. These results
suggest that deficient coupling of RGS4 to the membrane
target impaired the regulatory function of RGS4 and thus
failed to control the partial agonism of M2R-activated KG
currents.
Dual effects of pilocarpine on G-protein signalling
Our results demonstrated that RGS4-mediated inhibition
of G-protein signalling plays an important role in
the mechanism of partial agonism of M2R. A pre-
vious study indicated that RGS proteins are able to
influence the potency and maximal effect of μ–opioid
receptor agonists and suggested RGS proteins may
be more effective when the receptor/G-protein/effector
system is signalling at submaximal levels (Clark
et al. 2003). Indeed, we found that RGS4 suppressed
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Figure 4. Requirements of RGS4 domain for partial agonism of the M2R-activated KG currents
A, ACh (1 μM)-evoked KG currents (black) and pilocarpine (100 μM)-evoked KG currents (red) in oocytes expressing
wild-type RGS4 (a), without RGS4 expression (b) and expressing various RGS4 mutants (c–h) at –60 mV. B,
formations of truncated mutants of RGS4 and a point mutation in RGS domain. Black portions represent the
region of RGS domain. C, the response of pilocarpine-evoked KG currents relative to ACh-evoked KG currents was
calculated from steady state at −60 mV. The bar graph shows the means ± SEM, n = 6–9. The filled bars indicate
that the intact RGS domain is included in the mutants; the open bars indicate absence of the intact RGS domain
and a significant difference (P < 0.05) from the wild-type RGS4 group.
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KG currents in a pilocarpine concentration-dependent
manner, which reflects the controlling role of pilocarpine
in RGS4-mediated inhibition (Supporting information
Fig. S3). We assumed that the submaximal response of
the partial agonist is caused by promoting RGS-mediated
inhibition of G-protein signals.
To test this idea, we investigated the influence of
pilocarpine on RGS4-mediated inhibition. We analysed
the effect of pilocarpine on KG currents in the oocytes
that co-expressed with M2Rs and D2Rs because the
agonist concentration-dependent relaxation of M2R- and
D2R-activated KG currents were both modulated by
RGS4 (Supporting information Fig. S4). To examine the
effect of pilocarpine on the common G-protein-mediated
signalling, we recorded the D2R- and M2R-activated
KG currents and ensured that the total current was
below saturated state (Fig. 6). Co-expressions of M2R
and D2R in oocytes were separated into two groups
by injecting different concentrations of M2R cRNA: the
injected cRNA ratios of D2R toM2Rwere 100 for the high
M2R-expressing group (D/M = 100 group) and 1000 for
the low M2R-expressing group (D/M = 1000 group).
With co-treatment of dopamine and pilocarpine,
dopamine-evoked KG currents were defined by
subtracting the pilocarpine-evoked currents from
total currents. In the presence of RGS4, 0.1 μM
dopamine-evoked KG currents in the presence of
pilocarpinewere smaller than in the absence of pilocarpine
(D/M = 100 group, Fig. 6A and E). However, the pre-
sence or absence of pilocarpine yielded no difference
in the dopamine-evoked KG currents in the absence of
RGS4 (D/M = 100 group, Fig. 6B and E). This shows
the dual effects of pilocarpine: (1) like GPCR agonists,
it activates G-protein signal transduction; (2) it inhibits
G-protein-mediated activation of KG currents via RGS4.
Reduced or no expression of M2R produced mild or no
suppression of dopamine-evoked currents in the presence
of RGS4, respectively (D/M= 1000 group, Fig. 6C and E).
This suppression was not observed at low concentrations
of pilocarpine (data not shown). Certainly, dopamine
cannot evoke KG currents in oocytes deficient in D2R
(Fig. 6D and E). These results suggest that the binding of
pilocarpine to M2R promotes RGS4-mediated inhibition
of KG currents.
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Figure 5. Effects of a palmitoylation inhibitor
2–BP on agonist-evoked KG currents
ACh (1 μM)-evoked KG currents were recorded in
RGS4-expressing oocytes in vehicle (contained
0.1% ethanol) (A) or pretreatment with 2–BP
(100 μM) for 2 h (B) with a continuous test pulse as
showed on the right side of current traces. The
interval of each pulse is 3 s. Relative KG currents of
pilocarpine (100 μM) to ACh (1 μM) were recorded in
the same oocyte at −60 mV in the presence of vehicle
(C) or 2–BP (D). Basal currents were subtracted.
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Discussion
The novel findings in the present study are as follows: (1)
RGS4 is essential for partial agonism ofM2R-activated KG
currents; (2) functional coupling within the ligand–M2R
complex/G-protein/RGS4 system controls the partial
agonism; (3) pilocarpine suppresses G-protein-mediated
signalling via promoting the RGS-mediated inhibition.
In theheart,ACh increasesKG currents and thus induces
bradycardia (Hibino et al. 2010). The muscarinic partial
agonist pilocarpine, which is widely used in glaucoma
and xerostomia treatments, also decelerates the heart rate
via upregulating K+ flow (Wang et al. 1999). Here we
demonstrated that RGS4 is essential for reconstituting
partial agonism of cardiac M2R-activated KG currents.
Pilocarpine-evoked KG currents showed a different
A
B
D
– RGS4
100 µM pilocarpine
0 mV
–60 mV 200 ms
40 mV (200 ms)
+ RGS4
1 µA
30 s
0.1 µM dopamine 0.1 µM dopamine 1 mM Ba2+
100 µM pilocarpine 0.1 µM dopamine 0.1 µM dopamine 1 mM Ba2+
1 µA
30 s
– M2R
100 µM pilocarpine 0.1 µM dopamine 0.1 µM dopamine
1 µA
30 s
1 mM Ba2+
– D2R
0.5 µA
30 s
0.1 µM dopamine 1.0
0.8
0.6
0.4
0.2
0D
op
am
in
e-
in
du
ce
d 
cu
rr
en
ts
(+
pi
lo
ca
rp
in
e/
–p
ilo
ca
rp
in
e)
D2R
M2R
RGS4
+
+
+
+
+
–
+
–
+
?
+
+
–
+
+
+
–
+
+
D/M=100 D/M=1000
C
E
Figure 6. Suppression of dopamine-evoked KG currents by pilocarpine via RGS4 and M2R
Agonist-evoked KG currents were recorded in oocytes expressing D2R and M2R (injected cRNA ratio of D2R to
M2R = 100, D/M = 100) with (A) or without (B) RGS4 by a continuous test pulse as shown above the current
traces. The bars above each trace indicate the application of dopamine, pilocarpine and K+ channel blocker Ba2+.
C, the current recorded in an oocyte that did not express M2R. D, the current recorded in an oocyte that did not
express D2R. E, the ratio of dopamine-evoked currents in the presence of pilocarpine (100μM) to dopamine-evoked
currents in the absence of pilcarpine at−60mV. Basal and pilocarpine-evoked currents were subtracted. D/M= 100
indicates the high M2R-expressing group and D/M = 1000 indicates the lowM2R-expressing group (injected cRNA
ratio of D2R to M2R = 1000). Data show the mean ± SEM, n = 6. ∗ indicates a significant difference (P < 0.05).
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time-dependent current change from ACh-evoked KG
currents in rat atrial myocytes (Fig. 1). This current
characteristic resembles the hyperpolarization-elicited KG
currents in cat atrial myocytes (Moreno-Galindo et al.
2011). The study suggested that the time-dependent
decrease of pilocarpine-evoked KG current is caused by
the decreased affinity of pilocarpine for M2R when the
membrane becomes hyperpolarized. However, we did
not observe a similar decrease in oocytes lacking RGS4,
suggesting the decrease of pilocarpine-evoked KG currents
under hyperpolarization is determined by RGS4 and not
by agonist binding affinity. The divergent characteristic
and efficacy between pilocarpine and ACh should be due
to the different level of RGS4-mediated inhibition on KG
currents when different agonists bind to M2R.
We showed that pilocarpine became almost as
efficacious as ACh in oocytes lacking RGS4 (Fig. 2). In
pancreatic β-cells, RGS4 deficiency can also be found
to promote the M3 muscarinic receptor agonist-induced
calcium and insulin release (Ruiz de Azua et al.
2010). In RGS-insensitive C6μ-GαoPTXi cells, the
agonist-mediated inhibition of adenylyl cyclase became
particularly marked for the partial μ–agonist morphine
when compared with C6μ-GαoRGS/PTXi cells (Clark et
al. 2003). These results strongly suggested that the efficacy
of GPCR agonists can be modulated by RGS proteins.
We had demonstrated that RGS4 determined the
diverse response upon the binding of partial agonists
or full agonists as described above. However, the
underlying mechanism between the agonist–receptor
complex and RGS4 when different agonists bind to
M2R remains an enigma. It has been reported that
conformational changes of M2R are induced by agonist
binding and membrane voltage (Ben-Chaim et al. 2006;
Navarro-Polanco et al. 2011). The binding of pilocarpine
induced a different movement of the M2R voltage sensor
from that induced by ACh (Navarro-Polanco et al. 2011).
Diverse conformational changes in the receptor may alter
the interactions between the agonist–receptor complex
and its direct downstream signal molecules.
Furthermore, we found that the relative efficacy
of pilocarpine to ACh was decreased at more
negative potentials in the presence of RGS4 but
not in the absence of RGS4 (Fig. 3), suggesting
RGS4 inhibits pilocarpine-evoked KG currents in a
voltage-dependent manner. The voltage dependence of
RGS4-mediated inhibition probably reflects the alteration
of agonist–receptor complex–RGS4 interaction when
agonist–M2R conformation are changed uponmembrane
potentials.
Figures 4 and 5 show that the functional coupling
between the pilocarpine–M2R complex, Gα subunits and
RGS4 controls the partial agonism of M2R-activated
KG currents. Several residues in the RGS domain help
to stabilize the RGS4–Gα association and maintain the
RGS function of modulating KG currents (Srinivasa et
al. 1998; Inanobe et al. 2001). The regulatory function
of RGS4 is also impaired by 2–BP, which caused marked
redistribution of RGS4 from the plasma membrane to
cytosol in HEK293 cells (Bastin et al. 2012). These
findings suggest the normal function of RGS4 is supported
by RGS–Gα coupling and RGS4–membrane target
coupling.
Recent studies indicate that GPCRs interact with
RGS proteins, such as M2R/RGS4, M1 muscarinic
receptor/RGS2 and β2 adrenergic receptors/RGS2
(Abramow-Newerly et al. 2006; Jae´n & Doupnik, 2006).
The coupling of receptors and RGS proteins regulates
the affinity of RGS proteins for their G-protein targets
and the selectivity of RGS activity at the plasma
membrane (Abramow-Newerly et al. 2006; Jae´n &
Doupnik, 2006; Croft et al. 2013). Therefore, the
agonist–M2R complex may not only alter their inter-
action with RGS4 but also directly or indirectly
influence the RGS4–Gα association in a ligand-dependent
manner. We found that the pilocarpine–M2R complex
suppressed the G-protein-mediated activation of KG
currents via promoted RGS4-mediated inhibition (Fig. 6
and Supporting information Fig. S3). Therefore, the sub-
maximal efficacy of pilocarpine on KG currents may be
explained as follows: (1) decreased GEF activity, which is
caused by reducing the affinity of the pilocarpine–M2R
complex to Gα subunits; (2) promoted GAP activity,
which is caused by enhancing the interaction between the
agonist–receptor complex, Gα subunits and RGS.
This idea deserves further research because RGS
proteins play important roles in both physiology and
disease. RGS proteins not only modulate the heart rate
as described previously but are also responsible for
embryonic development, neurosecretion, etc. (Wang et
al. 1999; Hollinger & Hepler, 2002; Cifelli et al. 2008).
As a result of their negative regulatory effects in GPCR
signalling, RGS proteins are potential targets for treating
several diseases, such as Alzheimer’s disease (Neubig &
Siderovski, 2002). Although there are no useful inhibitors
of RGS that have been confirmed to suppress RGS4
function in native systems so far, we still need to clarify the
role of RGS proteins in partial agonism in physiological
conditions by further experimental processes and designs
in our future studies.
In rat atrial myocytes, GTPγS-induced irreversible
activation of KG channels eliminated the current character
and efficacy difference of agonist-evoked KG currents
(Supporting information Fig. S2). Therefore, the GTP
hydrolysis in the Gα subunits is crucial for partial agonism
in native GPCR signalling. An emerging paradigm is
that GAPs, such as RGS4, are major players in partial
agonism in cooperation with GEFs. By regulating the GTP
hydrolysis, RGS4 could control the G-proteins and thus
determine the effector activation.
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In summary, the partial agonism of M2R-activated KG
currents represents a merged outcome of the decreased
efficacy of GEFs and the enhanced efficacy of GAPs when
partial agonists bind to receptors. This finding helps us to
understand the molecular components and mechanisms
underlying the partial agonism of M2R-mediated physio-
logical responses and may be applicable to other
RGS-coupled GPCR signalling.
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